Whilst inhibiting early tumorigenic events, mir-326 could suppress the expression of therapy-sensitivity genes (NOTCH, RB1, PIK3CA) thereby conferring sorafenib resistance to HCC cells. This evidence concerns the gene RB1 and hepatocellular carcinoma.